Paquinimod, an orally active immunomodulatory quinoline-3-carboxamide derivative, which blocks the interaction of S100A9 with TLR4 and receptors for advanced glycation end products (RAGE), prevented upregulation of Lcn2 and S100A8/A9 in the brain and S100A8/A9 in the colon and ameliorated symptoms of colitis [138, 153, 160, 161]. This evidence concerns the gene IGKV1D-22 and colitis.